306 related articles for article (PubMed ID: 6924073)
1. Modulation of complement by autoimmune antibodies isolated from sera of patients with membranoproliferative glomerulonephritis and systemic lupus erythematosus.
Daha MR; Van Es LA
Neth J Med; 1982; 25(7):202-7. PubMed ID: 6924073
[No Abstract] [Full Text] [Related]
2. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
[TBL] [Abstract][Full Text] [Related]
3. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
4. Herpes gestationis associated with the C3 nephritic factor.
Grimwood R; Arroyave CM; Weston WL; Aeling JL
Arch Dermatol; 1980 Sep; 116(9):1045-7. PubMed ID: 6998378
[TBL] [Abstract][Full Text] [Related]
5. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
6. [Complement and nephritic activity in membranoproliferative glomerulonephritis].
Lévy M; Sich M; Habib R
Arch Fr Pediatr; 1979 Nov; 36(9 Suppl):LXIV-LXXIV. PubMed ID: 539879
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
Lanzer G; Pogglitsch H; Tilz GP
Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the knowledge of complement. II. Nephritic factors].
Leibowitch J; Lesavre P
Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
[No Abstract] [Full Text] [Related]
9. [Direct detection C3bBb stabilizing activity in sera from hypocomplementaemic membranoproliferative glomerulonephritis (MPGN) and complement profiles of C3NeF positive cases].
Watanabe S; Ohi H; Seki M; Fujita T; Hatano M
Nihon Jinzo Gakkai Shi; 1985 Oct; 27(10):1345-52. PubMed ID: 4094159
[No Abstract] [Full Text] [Related]
10. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
Ito S; Tamura N; Fujita T
Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
[TBL] [Abstract][Full Text] [Related]
11. A hemolytic method for the measurement of nephritic factor.
West CD
J Immunol Methods; 2008 Jun; 335(1-2):1-7. PubMed ID: 18410942
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
Whaley K; Ward D; Ruddy S
Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
[TBL] [Abstract][Full Text] [Related]
13. Relationship between the component and regulatory proteins of the classical pathway C3 convertase.
Welch TR; Forristal J; Beischel L
J Lab Clin Med; 1986 Jun; 107(6):529-33. PubMed ID: 3635565
[TBL] [Abstract][Full Text] [Related]
14. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases].
Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707
[No Abstract] [Full Text] [Related]
15. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
16. C5 measurement in membranoproliferative glomerulonephritis patients with C3 nephritic factor.
Ohi H; Watanabe S; Seki M; Fujita T; Ohmori F; Hatano M
Nephron; 1987; 46(2):217-8. PubMed ID: 3600936
[No Abstract] [Full Text] [Related]
17. Nephritic factor (NeF) of alternate pathway (NeFA) and of classical pathway (NeFc).
Arakawa M; Seino J; Kinoshita Y; Fukuda K; Saito T; Furuyama T
Tohoku J Exp Med; 1982 Dec; 138(4):401-9. PubMed ID: 6897686
[TBL] [Abstract][Full Text] [Related]
18. A case of hypocomplementemic mesangiocapillary glomerulonephritis: appearance of C3 NeF and another factor.
Seki M; Ohi H; Watanabe S; Kojima H; Fujita T; Hatano M
Nihon Jinzo Gakkai Shi; 1987 May; 29(5):585-8. PubMed ID: 3656714
[No Abstract] [Full Text] [Related]
19. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
[TBL] [Abstract][Full Text] [Related]
20. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
